List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. Europe Drug Discovery Market, 2019-2030, $ mn 19
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of Europe Drug Discovery Market 25
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 29
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 29
Figure 9. Primary Restraints and Impact Factors of Europe Drug Discovery Market 32
Figure 10. Investment Opportunity Analysis 36
Figure 11. Porter’s Fiver Forces Analysis of Europe Drug Discovery Market 39
Figure 12. Breakdown of Europe Drug Discovery Market by Drug Type, 2019-2030, % of Revenue 44
Figure 13. Europe Addressable Market Cap in 2021-2030 by Drug Type, Value ($ mn) and Share (%) 44
Figure 14. Europe Drug Discovery Market by Drug Type: Small Molecule Drugs, 2019-2030, $ mn 45
Figure 15. Europe Drug Discovery Market by Drug Type: Biologic Drugs, 2019-2030, $ mn 46
Figure 16. Breakdown of Europe Drug Discovery Market by Service, 2019-2030, % of Sales Revenue 48
Figure 17. Europe Addressable Market Cap in 2021-2030 by Service, Value ($ mn) and Share (%) 48
Figure 18. Europe Drug Discovery Market by Service: Medicinal Chemical Services, 2019-2030, $ mn 49
Figure 19. Europe Drug Discovery Market by Service: Biological Services, 2019-2030, $ mn 50
Figure 20. Europe Drug Discovery Market by Service: Drug Metabolism and Pharmacokinetics (DMPK) Services, 2019-2030, $ mn 51
Figure 21. Europe Drug Discovery Market by Service: Other Pharmaceutical Services, 2019-2030, $ mn 52
Figure 22. Breakdown of Europe Drug Discovery Market by Process, 2019-2030, % of Sales Revenue 54
Figure 23. Europe Addressable Market Cap in 2021-2030 by Process, Value ($ mn) and Share (%) 54
Figure 24. Europe Drug Discovery Market by Process: Target Selection, 2019-2030, $ mn 55
Figure 25. Europe Drug Discovery Market by Process: Target Validation, 2019-2030, $ mn 56
Figure 26. Europe Drug Discovery Market by Process: Hit-To-Lead Identification, 2019-2030, $ mn 57
Figure 27. Europe Drug Discovery Market by Process: Lead Optimization, 2019-2030, $ mn 58
Figure 28. Europe Drug Discovery Market by Process: Candidate Validation, 2019-2030, $ mn 59
Figure 29. Breakdown of Europe Drug Discovery Market by Technology, 2019-2030, % of Revenue 61
Figure 30. Europe Addressable Market Cap in 2021-2030 by Technology, Value ($ mn) and Share (%) 61
Figure 31. Europe Drug Discovery Market by Technology: High Throughput Screening, 2019-2030, $ mn 62
Figure 32. Europe Drug Discovery Market by Technology: Combinatorial Chemistry, 2019-2030, $ mn 63
Figure 33. Europe Drug Discovery Market by Technology: Pharmacogenomics and Pharmacogenetics, 2019-2030, $ mn 64
Figure 34. Europe Drug Discovery Market by Technology: Nanotechnology, 2019-2030, $ mn 65
Figure 35. Europe Drug Discovery Market by Technology: Bioanalytical Instruments, 2019-2030, $ mn 66
Figure 36. Europe Drug Discovery Market by Technology: Biochips, 2019-2030, $ mn 67
Figure 37. Europe Drug Discovery Market by Technology: Bioinformatics, 2019-2030, $ mn 68
Figure 38. Europe Drug Discovery Market by Technology: Other Technologies, 2019-2030, $ mn 69
Figure 39. Breakdown of Europe Drug Discovery Market by Therapeutic Area, 2019-2030, % of Revenue 71
Figure 40. Europe Addressable Market Cap in 2021-2030 by Therapeutic Area, Value ($ mn) and Share (%) 71
Figure 41. Europe Drug Discovery Market by Therapeutic Area: Oncology, 2019-2030, $ mn 72
Figure 42. Europe Drug Discovery Market by Therapeutic Area: Neurology, 2019-2030, $ mn 73
Figure 43. Europe Drug Discovery Market by Therapeutic Area: Infectious and Immune System Diseases, 2019-2030, $ mn 74
Figure 44. Europe Drug Discovery Market by Therapeutic Area: Digestive System Diseases, 2019-2030, $ mn 75
Figure 45. Europe Drug Discovery Market by Therapeutic Area: Cardiovascular Diseases, 2019-2030, $ mn 76
Figure 46. Europe Drug Discovery Market by Therapeutic Area: Diabetes, 2019-2030, $ mn 77
Figure 47. Europe Drug Discovery Market by Therapeutic Area: Respiratory Disease, 2019-2030, $ mn 78
Figure 48. Europe Drug Discovery Market by Therapeutic Area: Other Therapeutic Areas, 2019-2030, $ mn 79
Figure 49. Breakdown of Europe Drug Discovery Market by End User, 2019-2030, % of Revenue 80
Figure 50. Europe Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%) 81
Figure 51. Europe Drug Discovery Market by End User: Pharmaceutical Companies, 2019-2030, $ mn 82
Figure 52. Europe Drug Discovery Market by End User: Contract Research Organizations (CROs), 2019-2030, $ mn 83
Figure 53. Europe Drug Discovery Market by End User: Research Institutes, 2019-2030, $ mn 84
Figure 54. Europe Drug Discovery Market by End User: Other End Users, 2019-2030, $ mn 85
Figure 55. Breakdown of European Drug Discovery Market by Country, 2019 and 2030, % of Revenue 87
Figure 56. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 88
Figure 57. Drug Discovery Market in Germany, 2019-2030, $ mn 89
Figure 58. Drug Discovery Market in U.K., 2019-2030, $ mn 92
Figure 59. Drug Discovery Market in France, 2019-2030, $ mn 95
Figure 60. Drug Discovery Market in Spain, 2019-2030, $ mn 97
Figure 61. Drug Discovery Market in Italy, 2019-2030, $ mn 99
Figure 62. Drug Discovery Market in Russia, 2019-2030, $ mn 101
Figure 63. Drug Discovery Market in Rest of Europe, 2019-2030, $ mn 103
Figure 64. Growth Stage of Europe Drug Discovery Industry over the Forecast Period 105
Europe drug discovery market was valued at $14.8 billion in 2020 and will grow by 8.3% annually over 2020-2030 owing the rising demand for specialty medicines, the surge in lifestyle-oriented diseases and the advancements in technology, the growing elderly population and the rising healthcare expenses, rising expenditure on R&D, and expiration of patents. Highlighted with 36 tables and 64 figures, this 123-page report “Europe Drug Discovery Market 2020-2030 by Drug Type (Small Molecule, Biologics), Service (Medicinal, Biological, DMPK), Process, Technology, Therapeutic Area, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe drug discovery market in every aspect of the classification from perspectives of Drug Type, Service, Process, Technology, Therapeutic Area, End User, and Country. Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Small Molecule Drugs • Biologic Drugs Based on Service, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Medicinal Chemical Services • Biological Services • Drug Metabolism and Pharmacokinetics (DMPK) Services • Other Pharmaceutical Services Based on Process, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Target Selection • Target Validation • Hit-To-Lead Identification • Lead Optimization • Candidate Validation Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • High Throughput Screening • Combinatorial Chemistry • Pharmacogenomics and Pharmacogenetics • Nanotechnology • Bioanalytical Instruments • Biochips • Bioinformatics • Other Technologies Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Oncology • Neurology • Infectious and Immune System Diseases • Digestive System Diseases • Cardiovascular Diseases • Diabetes • Respiratory Disease • Other Therapeutic Areas Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Pharmaceutical Companies • Contract Research Organizations (CROs) • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Drug Type, Service, and Therapeutic Area over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Inc. Agilent Technologies Inc. Astrazeneca plc Bayer AG Charles River Laboratories International Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd GlaxoSmithKline PLC Merck & Co. Inc. Novartis AG Pfizer Inc. Shimadzu Corp Thermo Fisher Scientific Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More